Genome-wide analysis Policy for advanced analysis of 92,000 patients with cancer and intractable diseases

Genome-wide analysis Policy for advanced analysis of 92,000 patients with cancer and intractable diseases December 20, 15:22

k10012222541_201912201526_201912201527.mp4

The Ministry of Health, Labor and Welfare announced the future implementation plan for "genome-wide analysis" that examines all genetic information of patients and leads to effective treatment and development of new drugs. Over the next three years, we plan to analyze up to 92,000 cancer and intractable patients in advance.

Genomic medicine is linked to treatment by investigating the genetic information of patients and finding the most suitable drug, etc. Had been.

In response to this, the Ministry of Health, Labor and Welfare decided to promote “genome-wide analysis” to analyze all genetic information for cancer patients and patients with intractable diseases, and announced its implementation plan on the 20th.

First of all, we are going to lead in analyzing the approximately 28,000 persons of the approximately 64,000 persons and incurable patients of cancer patients at the maximum both to the prospect of the next three years.

Of these, genetic information of patients with refractory cancers with relatively low 5-year survival rates and rare cancers such as childhood cancer, and patients with muscular dystrophy and Parkinson's disease are intractable.

The policy is to analyze samples stored in research institutions and newly provided samples from the patient with the consent of the patient.

The Ministry of Health, Labor and Welfare wants to collect data by conducting genome-wide analysis, leading to effective treatment, diagnosis, and development of new drugs.